Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035108 | 0.85 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL3295203 | 0.85 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL1695341 | 0.81 | — | — | |
| SCHEMBL3707049 | 0.81 | KDM4E (0.36) | FFAR3 | |
| SCHEMBL30785992 | 0.77 | FFAR3 (0.38) | FFAR3 | |
| SCHEMBL28592530 | 0.77 | FFAR3 (0.38) | FFAR3 | |
| SCHEMBL14676814 | 0.76 | — | — | |
| SCHEMBL25408629 | 0.73 | — | — | |
| SCHEMBL14829034 | 0.70 | ASGR1 (0.31) | — | |
| SCHEMBL25349822 | 0.70 | FFAR3 (0.32) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2235012-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA SA (ES) | 2013-07-17 | — | — | EP | disclosed |
| US-8431580-B2 | 4-aminopyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA, S.A. (ES) | 2013-04-30 | — | — | US | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110039817-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S.L.U. (ES) | 2011-02-17 | — | — | US | disclosed |
| EP-2276730-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2235012-A2 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGOSNISTS | Palau Pharma, S.A. (ES) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009131669-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009115496-A1 | FURO [3, 2-D] PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009080721-A2 | 4 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009077608-A1 | 2 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009068512-A1 | 2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS | PALAU PHARMA, S. A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009056551-A1 | FURO[3,2-D]PYRIMIDINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039817-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | FFAR3 454/4885 |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | FFAR3 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.